NCCN Anal Carcinoma Panel Members

* Paul F. Engstrom, MD/Chair †
  Fox Chase Cancer Center

Juan Pablo Arnoletti, MD ¶
University of Alabama at
Birmingham Comprehensive Cancer Center

* Al B. Benson, III, MD †
  Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Yi-Jen Chen, MD, PhD §
City of Hope

Michael A. Choti, MD ¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Harry S. Cooper, MD ≠
Fox Chase Cancer Center

Raza A. Dilawari, MD ¶
St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute

Dayna S. Early, MD ≠
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Marwan G. Fakih, MD †
Roswell Park Cancer Institute

James Fleshman, Jr., MD ¶
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Charles Fuchs, MD †
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Jean L. Grem, MD †
UNMC Eppley Cancer Center at The Nebraska Medical Center

Krystyna Kiel, MD §
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

James A. Knol, MD ¶
University of Michigan Comprehensive Cancer Center

Lucille A. Leong, MD †
City of Hope Cancer Center

Edward Lin, MD †
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Kirk A. Ludwig, MD ¶
Duke Comprehensive Cancer Center

Mary F. Mulcahy, MD ‡
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Sujata Rao, MD †
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Leonard Saltz, MD † ‡ ¶
Memorial Sloan-Kettering Cancer Center

David Shibata, MD ¶
H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida

John M. Skibber, MD ¶
The University of Texas M. D. Anderson Cancer Center

James Thomas, MD
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

Alan P. Venook, MD † ‡
UCSF Comprehensive Cancer Center

† Medical Oncology
§ Radiotherapy/Radiation oncology
¶ Surgery/Surgical oncology
≠ Pathology
‡ Hematology/Hematology Oncology
¶ Internal medicine
¤ Gastroenterology
* Writing Committee Member

Continue
These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2007.
Summary of the Guidelines updates

Summary of changes in the 1.2008 version of the Anal Carcinoma Guidelines from the 1.2007 version include:

**ANAL-1**
- The following was added to footnote "c", "In a randomized trial, 5-FU + cisplatin + RT was not superior to 5-FU + mitomycin + RT".

**ANAL-2**
- PET scan was removed from the Workup of an anal margin lesion.

**ANAL-3**
- Footnote "g" - "If patient with an initially tethered tumor returns, 6 weeks postop RT, with a mobile but suspicious mass, consider biopsy."
- For patients in complete remission, a chest x-ray was added to surveillance. Abdominal CT was removed as a recommendation.
- For patients with progressive disease, the recommendation to "restage" was added after "Biopsy proven".
**CLINICAL PRESENTATION**

- Anal canal cancer

**WORKUP\(^b\)**

- Digital rectal examination (DRE)
- Inguinal lymph node evaluation
- Biopsy or FNA if suspicious nodes
- Chest x-ray or Chest CT
- Anoscopy
- Abdominal/pelvic CT or MRI
- PET scan
- Consider HIV testing + CD4 level if indicated
- Gynecological exam for women, including screening for cervical cancer

**CLINICAL STAGE**

<table>
<thead>
<tr>
<th>T1-T2, N0</th>
<th>Mitomycin/5-FU(^c) + RT (45(^d)-59 Gy)</th>
<th>See Follow-up Therapy and Surveillance (ANAL-3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T3-T4, N0 or Any T, N+</td>
<td>Mitomycin/5-FU(^c) + RT (55-59 Gy)(^e,f)</td>
<td>See Follow-up Therapy and Surveillance (ANAL-3)</td>
</tr>
</tbody>
</table>

**PRIMARY TREATMENT**

- For melanoma histology, see the [NCCN Melanoma Guidelines](#)
- For adenocarcinoma, see the [NCCN Rectal Cancer Guidelines](#)
- HPV testing does not contribute to management for invasive cancer.
- Re-evaluate at 45 Gy, if persistent disease, consider increasing to 55-59 Gy.
- Include bilateral inguinal/low pelvic nodal regions based upon estimated risk of inguinal involvement.
- Patients with anal cancer as the first manifestation of HIV/AIDS, may be treated with same regimen as non-HIV patient. Patients with active HIV/AIDS-related complications or a history of complications (eg, malignancies, opportunistic infections) may not tolerate full-dose therapy or may not tolerate mitomycin and require dosage adjustment or treatment without mitomycin.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## Anal Margin Cancer

### CLINICAL PRESENTATION

**Anal margin lesion**

- Biopsy: squamous cell carcinoma*<sup>a</sup>

### WORKUP<sup>b</sup>

- Digital rectal examination (DRE)
- Inguinal lymph node evaluation
  - Biopsy or FNA if suspicious nodes
- Chest x-ray or Chest CT
- Anoscopy
- Abdominal/pelvic CT or MRI
- Consider HIV testing + CD4 level if indicated
- Gynecological exam for women, including screening for cervical cancer

### CLINICAL STAGE

<table>
<thead>
<tr>
<th>Stage</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1, N0</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>T2-T4, N0 or Any T, N+</td>
<td>Mitomycin/5-FU&lt;sup&gt;c&lt;/sup&gt; + RT (55-59 Gy)&lt;sup&gt;e,f&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

### PRIMARY TREATMENT

<table>
<thead>
<tr>
<th>Adequate margins</th>
<th>Observe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate margins</td>
<td>Re-excision (preferred) or Consider local RT ± 5-FU-based chemotherapy</td>
</tr>
</tbody>
</table>

### Note:

- All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*For melanoma histology, see the [NCCN Melanoma Guidelines](#), for adenocarcinoma, see the [NCCN Rectal Cancer Guidelines](#).*

*HPV testing does not contribute to management for invasive cancer.*


*Include bilateral inguinal/low pelvic nodal regions based upon estimated risk of inguinal involvement.*

*Patients with anal cancer as the first manifestation of HIV/AIDS, may be treated with same regimen as non-HIV patient. Patients with active HIV/AIDS-related complications or a history of complications (eg, malignancies, opportunistic infections) may not tolerate full-dose therapy or may not tolerate mitomycin and require dosage adjustment or treatment without mitomycin.*
FOLLOW-UP

- Progressive disease
  - Biopsy proven
  - Restage

SURVEILLANCE

- Biopsy proven persistent disease
  - Reevaluate in 4 wks

RECURRENT/METASTATIC DISEASE

- 5-FU/Cisplatin
  - Absence
  - Abdominoperineal resection (APR)

- Every 3-6 mo for 5 y
  - Inguinal node palpation
  - CT scan

- Local recurrence
  - Inguinal node recurrence
  - Distant metastasis

- APR + groin dissection, if positive inguinal nodes

- Every 3-6 mo for 5 y
  - Inguinal node palpation
  - CT scan

- Continuous observation and reevaluate in 3 mo

- Clinical trial

- Cisplatin-based chemotherapy

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

9. If patient with an initially tethered tumor returns 6 weeks postop RT with a mobile but suspicious mass, consider biopsy.

h. Consider muscle flap reconstruction.

i. There is no evidence supporting resection of metastatic disease.

j. Cisplatin/5-fluorouracil recommended for metastatic disease. If this regimen fails, no other regimens have shown to be effective.
# Staging Anal Canal Cancer

**Table 1**

<table>
<thead>
<tr>
<th>2002 American Joint Committee on Cancer (AJCC) Staging System for Anal Canal Cancer*†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Tumor (T)</strong></td>
</tr>
<tr>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>T2</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T4</td>
</tr>
<tr>
<td><strong>Regional Lymph Nodes (N)</strong></td>
</tr>
<tr>
<td>NX</td>
</tr>
<tr>
<td>N0</td>
</tr>
<tr>
<td>N1</td>
</tr>
<tr>
<td>N2</td>
</tr>
<tr>
<td>N3</td>
</tr>
<tr>
<td><strong>Distant Metastasis (M)</strong></td>
</tr>
<tr>
<td>MX</td>
</tr>
<tr>
<td>M0</td>
</tr>
<tr>
<td>M1</td>
</tr>
</tbody>
</table>

**Stage Grouping**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T4</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**Histologic Grade (G)**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Well differentiated</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>G2</td>
<td>Poorly differentiated</td>
</tr>
<tr>
<td>G3</td>
<td>Undifferentiated</td>
</tr>
</tbody>
</table>

---

*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed written permission of Springer-Verlag New York on behalf of the AJCC.

†Direct invasion of the rectal wall, perirectal skin, subcutaneous tissue, or the sphincter muscle(s) is not classified as T4.
## Staging Anal Margin Cancer

### Table 2

2002 American Joint Committee on Cancer (AJCC)
TNM Staging System for Skin Cancer*

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>Stage Grouping</th>
</tr>
</thead>
</table>
| TX                                    | Stage 0  
T0                                    | Tis N0 M0                                                                      |
| T1                                    | Stage I  
T2                                    | T1 N0 M0                                                                      |
| T3                                    | Stage II 
T4                                    | T2 N0 M0                                                                      |
| T5                                    | Stage III 
Any T                                 | T3 N0 M0                                                                      |
|                                        | Stage IV 
Any T                                 | Any T N1 M0                                                                  |

**Histologic Grade (G)**

- **GX** Grade cannot be assessed
- **G1** Well differentiated
- **G2** Moderately differentiated
- **G3** Poorly differentiated
- **G4** Undifferentiated

*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the *AJCC Cancer Staging Manual, Sixth edition* (2002) published by Springer-Verlag New York. (For more information, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed written permission of Springer-Verlag New York on behalf of the AJCC.

### Notes

- Regional Lymph Nodes (N)
  - **NX** Regional lymph nodes cannot be assessed
  - **N0** No regional lymph node metastasis
  - **N1** Regional lymph node metastasis

- Distant Metastasis (M)
  - **MX** Distant metastasis cannot be assessed
  - **M0** No distant metastasis
  - **M1** Distant metastasis

†Anal margin tumors are biologically comparable to other skin tumors and therefore are classified by this schema.
This manuscript is being updated to correspond with the newly updated algorithm. Last update 08/20/07

NCCN Categories of Evidence and Consensus

**Category 1:** There is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate.

**Category 2A:** There is uniform NCCN consensus, based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 2B:** There is nonuniform NCCN consensus (but no major disagreement), based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 3:** There is major NCCN disagreement that the recommendation is appropriate.

All recommendations are category 2A unless otherwise noted.

**Overview**

An estimated 4,650 new cases (1,900 men and 2,750 women) of anal cancer (involving the anus, anal canal, or the anorectum) will occur in the United States in 2007, accounting for approximately 1.7% of digestive system cancers.¹ It has been estimated that 690 deaths due to anal cancer will occur in the U.S. in 2007. Although considered to be a rare type of cancer, the incidence of anal carcinoma in the U.S. increased by approximately 2-fold for men and 1.5-fold for women from the period of 1973-1979 to 1994-2000² (see section entitled Risk Factors, below).

This manuscript summarizes the NCCN clinical practice guidelines for managing squamous cell anal carcinoma which represents the most common histologic form of the disease. Other types of cancers occurring in the anal region, such as adenocarcinoma or melanoma, are addressed in other NCCN guidelines (ie, anal adenocarcinoma and anal melanoma are managed according to the NCCN Rectal Cancer Guidelines and the NCCN Melanoma Guidelines, respectively). The recommendations in these guidelines are classified as category 2A except where noted, meaning that there is uniform NCCN consensus, based on lower-level evidence (including clinical experience), that the recommendation is appropriate. The panel unanimously endorses patient participation in a clinical trial over standard or accepted therapy.

**Risk Factors**

Anal carcinoma has been associated with human papilloma virus (HPV) infection (anal-genital warts); a history of receptive anal intercourse or sexually transmitted disease; a history of cervical, vulvar, or vaginal cancer; and immunosuppression after solid organ transplantation or human immunodeficiency virus (HIV) infection.³⁴ Currently, it is believed that the association between anal carcinoma and persistent infection with a high-risk form of HPV (eg, HPV-16) is strongest. For example, results of a study of tumor specimens from 60 pathology laboratories showed that HPV-16 was detected in 84% and 0% of the anal and rectal cancer specimens, respectively.⁴ Furthermore, suppression of the immune system by the use of immunosuppressive drugs or HIV infection is likely to facilitate persistence of HPV infection of the anal region.⁵⁶

**Anatomy/Histology**

The anal region is commonly considered to be made up of the anal canal and the anal margin. The anal canal is the more proximal portion of the anal region. Various definitions of the anal canal exist (eg, functional/surgical anal canal; anatomic anal canal; and histological anal canal) which are based on particular physical/anatomic landmarks or histological characteristics of the anal canal. The functional anal canal is associated with findings on digital rectal examination (DRE) and/or through imaging studies. The superior border of the functional...
Anal canal, separating it from the rectum, has been defined as the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring. The functional anal canal is approximately 3 to 4 cm in length and has an inferior border defined by the lowermost edge of the sphincter muscles which corresponds to the introitus of the anal orifice, otherwise known as the anal verge. However, perhaps the most useful definitions of the anal canal are those which include histologic characteristics of the mucosal lining of the anal region. The mucosa of the anal canal is predominantly formed by squamous epithelium, in contrast to the mucosa of the rectum which is lined with glandular epithelium. The most superior aspect of anal canal is a 1 to 2 cm zone between the anal and rectal epithelium which has rectal, urothelial, and squamous histologic characteristics. The most inferior aspect of the anal canal, approximately at the anal verge, corresponds to the area where the mucosa lined with modified squamous epithelium transitions to an epidermis-lined anal margin. The approximate proximal boundary of the anal margin is the anal verge, and the anal margin includes the perianal skin which surrounds the anal orifice over a 5 cm radius. The terms anal margin and perianal skin are frequently used synonymously.

Pathology

Most primary cancers of the anal canal are of squamous cell histology. The second edition of the World Health Organization (WHO) classification system of anal carcinoma designated all squamous cell carcinoma variants of the anal canal as cloacogenic and identified subtypes as large cell keratinizing, large cell non-keratinizing (transitional), or basaloid. It has been reported that squamous cell cancers in the more proximal region of the anal canal are more likely to be non-keratinizing and less differentiated. However, the terms cloacogenic, transitional, keratinizing and basaloid have been removed from the current WHO classification system of anal canal carcinoma, and all subtypes have been included under a single generic heading of squamous cell carcinoma. Reasons for this change include the following: both cloacogenic (which is sometimes used interchangeably with the term basaloid) and transitional tumors are now considered to be non-keratinizing tumors; it has been reported that both keratinizing and nonkeratinizing tumors have similar a natural history and prognosis; and a mixture of cell types frequently characterize histologic specimens of squamous cell carcinomas of the anal canal. No distinction between squamous anal canal tumors on the basis of cell type has been made in the guidelines. Other less common anal canal tumors include adenocarcinomas of the anal glands, small cell and undifferentiated cancers, and melanomas. Squamous cell carcinomas of the anal margin are more likely than anal canal tumors to be well-differentiated and keratinizing, but they are not characterized in the guidelines according to cell type. The presence of skin appendages (eg, sweat glands) in anal margin tumors can distinguish them from anal canal tumors. However, it is not always possible to distinguish between anal canal and anal margin squamous cell carcinoma since tumors can involve both areas.

Lymph node drainage of anal cancer tumors depends on the location of the tumor in the anal region. Anal cancers above the dentate line, are likely to drain to the internal iliac system, more proximally located lesions commonly drain to nodes of the inferior mesenteric system including the perirectal nodes, and lesions below the dentate line more typically drain to the superficial inguinal nodes and, to a lesser extent, to the femoral or external iliac lymph nodes. Therefore, distal anal cancers present with a higher incidence of inguinal node metastasis, although the lymphatic drainage systems throughout the anal canal are not isolated from each other.

Staging

The TNM staging system for anal canal cancer developed by the American Joint Committee on Cancer (AJCC) is detailed in Table 1.
Since current recommendations for the primary treatment of anal canal cancer do not involve a surgical excision, most tumors are staged clinically with an emphasis on the size of the primary tumor as determined by direct examination and microscopic confirmation. An incisional tumor biopsy is required. Rectal ultrasound to determine depth of tumor invasion is not used in the staging of anal cancer (see Clinical Presentation/Evaluation, below). The AJCC TNM system used for anal margin cancer is the same system used to stage skin cancer since the 2 types of cancers have a similar biology.

Lymph node involvement of specific regional lymph nodes is distinguished in the staging of anal canal cancer: N1 designates metastasis in one or more perirectal nodes; N2 represents metastasis in unilateral internal iliac nodes and/or inguinal node(s); and N3 designates metastasis in perirectal and/or inguinal nodes and/or bilateral internal iliac and/or inguinal nodes. For anal margin cancer, N0 and N1 simply represent the absence or presence of regional nodal metastasis. However, because initial therapy of anal cancer does not typically involve surgery, the true lymph node status may not be determined accurately. Biopsy of inguinal nodes is recommended if tumor metastasis to these nodes is suspected.

The prognosis of anal carcinoma is related to the size of the primary tumor and the presence of lymph node metastases. Approximately 60% to 70% of anal carcinoma tumors are initially staged as I or II. Overall, the 5-year survival rate for patients with tumors that are no more than 2 cm in diameter that are treated with chemoRT is approximately 80%, whereas the 5-year survival rate for patients 5 cm or more is less than 50%. Reports of the extent of nodal involvement associated with anal cancers at presentation have varied widely, with most values ranging between 10% and 40%. Although there have been reports that the extent of nodal involvement is correlated with the T-stage of the tumor, other studies have not supported this conclusion. In a surgical series of patients with anal cancer who underwent an abdominoperineal resection (APR), it was noted that pelvic nodal metastases were often under 0.5 cm, making routine radiological evaluation with CT and PET scan unreliable in the determination of lymph nodal involvement. In a retrospective study of 270 patients treated for anal canal cancer with RT between 1980 and 1996, synchronous inguinal node metastasis was observed in 6.4% of patients with tumors staged as T1 or T2, and increased to 16% in patients with T3 or T4 tumors. In a subset analysis of those patients with tumors characterized as T1-T2,N2-N3 and T3-T4,N2-N3, survival was shown to be related to T-stage rather than nodal involvement since respective 5-year survival rates of 72.7% and 39.9% were observed; however, the numbers of patients involved in this analysis were small.

Management of Anal Carcinoma

Clinical Presentation/Evaluation

Most patients with anal carcinoma present with rectal bleeding. Approximately 30% of patients with anal carcinoma have either pain or the sensation of a rectal mass. The recommendations of the NCCN Anal Carcinoma Guidelines panel for the clinical evaluation of patients with suspected anal canal or anal margin cancer are the same. Following confirmation of squamous cell carcinoma by biopsy, the panel recommends a thorough examination/evaluation, including a careful DRE, palpation of the inguinal lymph nodes, and an anoscopic examination with biopsy of suspicious lesions. Assessment of T stage is primarily performed through clinical examination. Assessment of inguinal lymph node involvement for either anal margin or anal canal cancer is performed by fine-needle aspiration (FNA) biopsy and/or excisional biopsy of nodes found to be enlarged by either clinical or radiological examination. Evaluation of pelvic lymph nodes with computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis is also recommended. These methods can also provide information on whether tumor involves other abdominal/pelvic organs.
Since veins of the anal region are part of the venous network associated with systemic circulation, chest x-ray or CT scan is performed to evaluate for pulmonary metastasis. Positron emission tomography (PET)/CT scan is useful in the evaluation of pelvic nodes, even in patients with anal canal cancer who have normal-sized lymph nodes on CT imaging. HIV testing and measurement of CD4 level is suggested as the risk of anal carcinoma has been reported in some studies to be higher in HIV-positive patients. Gynecological exam, including cervical cancer screening, is suggested for female patients due to the association of anal cancer and HPV. HPV testing does not contribute to the management of anal cancer.

**Primary Treatment of Anal Carcinoma**

In the past, patients with invasive anal carcinoma were routinely treated with an APR; however, local recurrence rates were high, 5-year survival was only 40% to 70%, and the morbidity with a permanent colostomy was considerable. Currently, concurrent chemoradiation (chemoRT) alone, as an alternative to an APR, is the recommended primary treatment for patients with anal canal cancer, or anal margin cancer characterized as T2-T4, N0 or node positive. Well differentiated anal margin lesions characterized as T1,N0 can be treated with margin-negative local excision alone.

In 1974, Nigro and coworkers observed complete tumor regression in some patients with anal carcinoma treated with preoperative 5-fluorouracil- (5-FU-) based concurrent chemoRT including either mitomycin or porfiromycin, suggesting that it might be possible to cure anal carcinoma without surgery and permanent colostomy. Subsequent nonrandomized studies using similar regimens and varied doses of chemotherapy and radiation provided support for this conclusion. Results of randomized trials evaluating the efficacy and safety of administering chemotherapy with RT support the use of combined modality therapy in the treatment of anal cancer. Results from a phase III study from the European Organization for Research and Treatment of Cancer (EORTC) comparing use of chemoRT (5-FU plus mitomycin) and RT alone in the treatment of anal carcinoma showed that patients in the chemoRT arm had a higher rate of locoregional control and a longer colostomy-free interval. The United Kingdom Coordinating Committee on Cancer Research (UKCCR) randomized trial confirmed that chemoRT with 5-FU and mitomycin was more effective in controlling local disease than RT alone (relative risk=0.54, 95% CI, 0.42-0.69; P<0.0001), although no significant differences in overall survival were observed.

A number of studies have addressed the efficacy and safety of specific chemoRT regimens (involving chemotherapy regimens containing both 1 and 2 agents) used in the treatment of anal carcinoma. In a phase III Intergroup study, patients receiving chemoRT with the combination of 5-FU and mitomycin had a lower colostomy rate (9% versus 22%; P = 0.002) and a higher disease-free survival (73% vs 51%; P = 0.0003) compared with patients receiving chemoRT with 5-FU alone, indicating that mitomycin is an important component of chemoRT in the treatment of anal carcinoma. Survival rate at 4 years was the same for the two groups reflecting the ability to salvage recurrent patients with an APR. Cisplatin as a substitute for mitomycin was evaluated in several phase II trials and results suggested that cisplatin-containing and mitomycin-containing chemoRT were comparable. Use of 5-FU-based chemoRT combined with either mitomycin or cisplatin in the treatment of patients with anal carcinoma has been investigated in the randomized Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 trial. Thus far, no significant differences have been observed in the primary endpoint, disease-free survival (DFS) (hazard ratio=1.15; 95% CI, 0.87-1.50; P=0.33). However, the colostomy rate was significantly higher in the group receiving cisplatin compared to the mitomycin-containing arm (hazard ratio=1.6; 95% CI, 1.008-2.63; P=0.04).
The optimal dose and schedule of RT for anal carcinoma also continues to be explored, in addition to the schedule of chemotherapy relative to RT. Most studies have delivered 5-FU as a protracted 90 to 120 hour infusion during the first and fifth weeks of RT, and bolus injection of mitomycin is typically given on the first or second day of the 5-FU infusion. The effects of RT dose and RT schedule have been evaluated in a number of nonrandomized studies. In one study of patients with early-stage (T1 or Tis) anal canal cancer, most patients were effectively treated with RT doses of 40-50 Gy for Tis lesions and 50-60 Gy for T1 lesions. In another study in which the majority of patients had stage II/III anal canal cancer, local control of disease was higher in the group of patients receiving RT doses ≥50 Gy. A third study in patients with T3, T4 or lymph node-positive tumors, RT doses of ≥ 54 Gy administered within 60 days were associated with increased local control. In the phase II RTOG 92-08 trial, planned 2 week treatment breaks in the delivery of chemoRT to patients with anal cancer were associated with increased local regional failure rates when compared with delivery of the same regimen of chemoRT without a treatment break, although the number of patients involved in this study was small and the differences were not significant. Although results of other studies have also supported the benefit of delivery of chemoRT over shorter time periods, treatment breaks in the delivery of chemoRT are frequently required (eg. up to 50% of patients in clinical trials undergo treatment breaks) since chemoRT-related toxicities are common. For example, it has been reported that one-third of patients receiving primary chemoRT for anal carcinoma at RT doses of 30 Gy in 3 weeks develop acute anoproctitis and dermatitis, increasing to one-half to two-thirds of patients when RT doses of 54-60 Gy are administered in 6 weeks. Of note, results of a phase II randomized trial of patients with locally advanced anal carcinoma sponsored by the EORTC showed that an estimated 3-year rate of local control of 88% could be attained with reasonable toxicity when a chemoRT regimen including a 2-week treatment gap was used. Some of the reported late side effects of chemoRT include urgency and increased frequency of defecation, chronic perineal dermatitis, dyspareunia, and impotence. In some cases, severe late RT complications, such as anal ulcers, stenosis, and necrosis, may necessitate surgery involving colostomy.

As discussed above (see Risk Factors), patients with HIV/AIDS have been reported to be at increased risk of anal carcinoma. Although most studies evaluating outcomes of patients with HIV/AIDS treated with chemoRT for anal carcinoma are retrospective, there is evidence to indicate that patients with anal carcinoma as the first manifestation of HIV/AIDS (especially those with a CD4 count of ≥200/mm3) may be treated with the same regimen as non-HIV patients. Other factors to consider include compliance with highly active antiretroviral therapy (HAART) (although it is unclear whether increased compliance with HAART is associated with better outcomes following chemoRT for anal carcinoma) and performance status. Patients with active HIV/AIDS-related complications or a history of complications (eg, malignancies, opportunistic infections) may not tolerate full-dose therapy and may require dosage adjustment.

**Recommendations for the Primary Treatment of Anal Canal Cancer**

Anal canal cancer is treated with chemoRT (5-FU/mitomycin plus RT) as the primary treatment option. Recommended RT doses are 36-40 Gy to potential areas of microscopic disease, such as the inguinal and high pelvic nodes, 45-59 Gy to gross disease for patients with disease clinically staged as T1-2,N0, and 55-59 Gy for those with disease staged as T3-T4, N0 or T any with nodal involvement. At least 2 cycles of 5-FU/mitomycin to be delivered during the first and fifth week of RT are recommended.

**Recommendations for the Primary Treatment of Anal Margin Cancer**

Anal margin lesions can be treated with either local excision or chemoRT depending on the clinical stage. Primary treatment for patients with T1,N0 well differentiated anal margin lesions, like that for
skin cancers, is by local excision with adequate margins. If the margins are not adequate, re-excision is the preferred treatment option. Local RT with or without 5-FU-based chemotherapy can be considered as an alternative treatment option when surgical margins are inadequate. T2 to T4 and node-positive anal margin cancers should be treated with mitomycin/5-FU plus RT (with doses and scheduling as described for anal canal cancers). Inclusion of bilateral inguinal/low pelvic nodal regions in the RT field should be considered for more advanced cancers.

Follow-up and Surveillance Following Primary Treatment

Following primary treatment, the surveillance and follow-up treatment recommendations for anal margin and anal canal cancer are the same. Patients are re-evaluated by DRE between 8 and 12 weeks after completion of primary treatment with chemoRT. A biopsy is performed only if presence of disease is suspected after serial DRE. Disease can continue to regress for a period of months following completion of chemoRT, and the likelihood of a false positive result is high. Some of the indications for biopsy include new hard-edged ulcer, enlarging mass, or increasing pain. Following re-evaluation, patients are classified according to whether they have a complete remission of disease, progressive disease, or persistent disease. In one study, persistent disease was defined as presence of biopsy-proven carcinoma within 6 months of completion of chemoRT. Although a clinical assessment of progressive disease requires histologic confirmation, patients can be classified as having a complete remission without biopsy verification, if clinical evidence of disease is absent. Patients with biopsy results of persistent disease but without evidence of progression may be managed with close follow-up (in 4 weeks) to see if further regression occurs. If no regression of disease is observed on serial examination or if progression of disease occurs, further intensive treatment is indicated (see Recommendations for the Treatment of Progressive Disease). Patients who continue to show evidence of disease regression should be re-evaluated clinically in 3 months. The panel recommends that patients classified as having a complete remission of disease should undergo more intensive surveillance every 3-6 months for 5 years, including DRE, anoscopy, endoscopic evaluation, inguinal node palpation, and annual abdominal/pelvic CT scans for 3 years for patients with locally advanced disease (ie, T3/T4 tumor) or node-positive cancers.

Treatment of Progressive/Recurrent/Metastatic Anal Carcinoma

Despite the effectiveness of chemoRT in the primary treatment of anal carcinoma, rates of locoregional failure of up to 40% have been reported, and radical salvage surgery with an APR has been the treatment of choice for these patients. Some of the disease characteristics that have been associated with higher recurrence rates following chemoRT include higher T stage, higher N stage, and positive HIV status. Results of several studies of patients undergoing a salvage APR for anal carcinoma have demonstrated 5-year survival rates of approximately 50% have been observed, although the rate of complications was reported to be high in some of these studies. Factors associated with worse prognosis following salvage APR include an initial presentation of node-positive disease and RT doses < 55 Gy used in the treatment of primary disease. It has been shown that for patients undergoing an APR which had been preceded by RT, closure of the perineal wound using rectum abdominus myocutaneous flap reconstruction resulted in decreased perineal wound complications.

It has been reported that the most common sites of metastasis outside of the pelvis include the liver, lung, and extrapelvic lymph nodes. Since anal carcinoma is a rare cancer and only 10%-20% of patients with anal carcinoma present with metastatic disease, only limited data are available on this population of patients, although there is some evidence to indicate that chemotherapy with a fluoropyrimidine-based...
Regimen plus cisplatin has some benefit in patients with metastatic anal carcinoma.\(^{50-52}\)

**Recommendations for the Treatment of Progressive Disease (Anal Canal/Margin Cancer)**

Evidence of progression found on DRE should be followed by biopsy as well as CT and PET imaging. Patients with biopsy-proven progressive disease are candidates for an APR or additional chemotherapy with 5-FU/cisplatin followed by an APR. Muscle flap reconstruction of the perineum should be considered because of the extensive previous RT to the area. These patients should be re-evaluated every 3-6 months for 5 years, including clinical evaluation of nodal metastasis (ie, inguinal node palpation) and CT scan.

**Recommendations for the Treatment of Locally Recurrent/Metastatic Disease (Anal Canal/Margin Cancer)**

Patients who are in complete remission should be evaluated every 3-6 months for 5 years as described (see Follow-up and Surveillance Following Primary Treatment). Treatment recommendations for patients who develop a local recurrence include an APR; muscle flap reconstruction of the perineum should be considered. Inguinal node dissection is reserved for recurrence in that area, and can be performed without an APR in cases where recurrence is limited to the inguinal nodes. Patients who develop inguinal node metastasis who do not undergo an APR can be considered for RT to the groin with or without chemotherapy if limited prior RT to the groin was given. Treatment recommendations for patients who develop a distant metastasis should be individualized, and local treatment, as described above, could be considered for the locally-symptomatic patient. There is no evidence supporting resection of metastatic disease. Treatment recommendations for patients with metastatic anal carcinoma include platinum-based chemotherapy or enrollment in a clinical trial. Currently, no other regimens have been shown to be effective in these patients following failure of cisplatin/5-FU.

**Summary**

The NCCN Anal Carcinoma Guidelines panel believes that a multidisciplinary approach, including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating patients with anal carcinoma. Recommendations for the primary treatment of anal margin cancer and anal canal cancer are very similar and include 5-FU/mitomycin-based RT, although small, well differentiated anal margin lesions can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all patients with anal carcinoma since salvage is possible. Patients with biopsy-proven evidence of locoregional progressive disease following primary treatment should receive either chemotherapy with 5-FU/cisplatin followed by an APR or surgery alone. Following complete remission of disease, patients with a local recurrence should be treated with an APR with a groin dissection if there is clinical evidence of inguinal nodal metastasis, and patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy, if limited prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with cisplatin-based chemotherapy or enrolled in a clinical trial. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

**Disclosures for NCCN Anal Carcinoma Guidelines Panel**

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers’ bureau participation. Members of the panel indicated that they have received support from the following: Abraxis, Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, ImClone, MedImmune, NCI, Novartis, Pfizer, Quality Oncology, Roche, Sanofi-Aventis,
Schering-Plough, Taiho, TissueLink Medical, U.S. Surgical and Valleylab/Tyco. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.
References


